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ABSTRACT
Objective: To determine “Is L-carnitine an effective treatment to improve the quality of life for
patients with Rett Syndrome?”
Study Design: Review of all English language randomized controlled trials and cohort trials from
1999-2007.
Data Sources: Randomized, placebo-controlled, double-blind crossover trial, randomized
controlled trial, and cohort trial comparing L-carnitine to placebo or control group were found
using OVID MEDLINE, and Cochrane Databases
Outcomes Measured: The trials measured the effects of L-carnitine on physical well-being,
motor skills, sleep efficiency, physical activity, and cardiac dysautonomia using the following
assessment tools: The Rett Syndrome: Symptom Severity Index (RT:SSI), Patient Well-Being
Index, SF-36 Health Survey, Hand Apraxia Scale, RS Motor Behavioral Assessment, 7 day-night
sleep diary, TriTrac-R3D ergometers, electrocardiogram.
Results: Two studies demonstrated that the patient well being, behavior/social and
orofacial/respiratory motor skills, sleep efficiency, sleep latency, proportion of total sleep that
occurred during the day, energy level, communication skills, expressive language, and teeth
grinding all improved with L-carnitine treatment. The third study demonstrated a reduction in
the risk for cardiac arrhythmias in treatment with L-carnitine. Parents/caregivers of participants
in the study reported minor side effects with treatment, but no major side effects were reported.
Conclusion: Based on the three trials, L-carnitine does improve the quality of life in patients with
Rett Syndrome.
Key Words: Rett Syndrome, L-carnitine
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Introduction
Rett Syndrome is a severe neurodevelopmental disorder that primarily affects females
and is defined by progressive loss of intellectual functioning and fine and gross motor skills,
deceleration of head growth, and the development of stereotypic hand movements occurring after
a period of normal development.1,2,3 The risk of sudden death is increased in Rett Syndrome
patients due to the occurrence of lethal arrhythmias, which can be related to long QT intervals
and/or low heart rate variability.3
Rett Syndrome is considered to be the second most common cause, after Down
syndrome, of severe mental retardation in girls. Its worldwide prevalence rate ranges from
1:10,000 to 1:23,000 live female births.1 Although the exact cost of medical care for patients
with Rett Syndrome is unknown, the syndrome is extremely difficult to manage and for some
health insurance policies it can be filed under a “pre-existing condition” which makes it nearly
impossible to obtain coverage for these patients. Also, the number of healthcare visits per year
for patients with Rett Syndrome varies depending on the severity of the disease and other
existing medical conditions.
The etiology of Rett Syndrome is unknown; however, in 80% of cases there is a mutation
of a methyl-CpG-binding protein 2 (MECP2).3
No treatments for Rett Syndrome as a whole currently exist; however, there are a variety
of ways to minimize the effects of Rett Syndrome by treating specific symptoms. Current
therapies include physical therapy, occupational therapy, speech-language therapists, anti-seizure
medication, OTC medications for constipation and indigestion. Another proposed therapy that is
being researched is treatment with L-carnitine. Evidence suggests that an underlying defect in
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Rett Syndrome may lie within mitochondrial energy production, which can interfere with the
active cellular carnitine uptake process.1,2,3
Objective
The objective of this systematic review is to determine whether or not “Is L-carnitine an
effective treatment to improve the quality of life for patient with Rett Syndrome?” Previous
studies have shown that a plasma carnitine deficiency exists in some patients with Rett
Syndrome; therefore it is suggested that Rett Syndrome patients will have positive outcomes
when treated with L-carnitine.
Methods
Randomized Controlled Trials were searched for those with a female patient population
over the age of 2 with clinically diagnosed Rett Syndrome, as well as those whose treatment
interventions include L-carnitine. In addition, only those articles that compared the treatment
groups receiving L-carnitine to a placebo group or control group were considered. Under these
criteria, one randomized, placebo-controlled, double-blind crossover trial, one cohort, and one
randomized controlled trial were identified and included in this review.
A detailed search was completed by the author using the following search engines: OVID
MEDLINE, Cochrane Database of Randomized Controlled Trials, and Cochrane Database of
Systemic Reviews. The key words “Rett Syndrome” and “L-Carnitine” were used in
combination to search for English articles and all of the resulting articles were published in peerreviewed journals from 1999 to 2007. The articles were selected based on the importance of the
outcomes to the patient (Patient Oriented Evidence That Matters, POEMS). Studies that were
included were those that were randomized, controlled, and based on patient oriented outcome.
Those that were excluded were studies in which the patients were neither female nor diagnosed
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with Rett Syndrome. Table 1 includes the demographics of the included studies. Results were
reported based on p-values, clinically importance (CI), relative risk reduction (RRR), absolute
risk reduction (ARR), relative benefit increase (RBI), absolute benefit increase (ABI), and
numbers needed to treat (NNT).
Outcomes Measured
The outcomes measured had to be POEMS, such as the positive effects of L-carnitine on
physical well-being, motor skills, sleep efficiency, physical activity, and cardiac
dysautonomia.1,2,3 To help measure these outcomes several tools were used. The Rett
Syndrome: Symptom Severity Index (RT:SSI), Patient Well-Being Index, and SF-36 Health
Survey were used to measure the physical well being of participants. The hand apraxia scale and
RS Motor Behavioral Assessment were used to measure motor skills. A 7 day-night sleep diary
was kept to measure sleep efficiency. TriTrac-R3D ergometers were used to measure physical
activity and cardiac dysautonomia was measured using an electrocardiogram. These tools were
used by parents/caregivers to assess the outcomes of the trials. To compare treatment score
differences the Wilcoxon matched-pair, signed-rank test was used.1,2,3
Table 1. Demographics of Included Studies
Study
Type
#
Age Inclusion Criteria
Pts (yrs)
Ellaway, Randomized, 39 4-35 Females
1999
placeboyo
diagnosed with
controlled,
Rett Syndrome
double-blind
crossover
trial

Exclusion W/D Interventions
Criteria
None
4
Phase 1- Group 1
received Lcarnitine and
Group 2 received
placebo both for
an 8 week period
followed by an 8
week wash-out
period. Phase 2Group 1 receive
placebo and
Group 2 received
L-carnitine for an
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Ellaway,
2001

Cohort

21

Guideri,
2005

Randomized 22
Control Trial

7-41 Females
yo
diagnosed with
Rett Syndrome

None

0

2-21 Females with Rett None
yo
Syndrome whose
diagnosis was
confirmed by 2
child
neuropsychiatrists

0

4

8 week period.
Subjects assessed
before treatment
and after a 6
month treatment
of L-carnitine
with the Rett
Syndrome
All participants
initially treated
with
carbamazepine.
Participants
divided into 2
groups: one
group received
Acetyl-Lcarnitine
treatment for 6
months and the
other group was
the control group.

Results
Two randomized controlled trials and one cohort trial are presented in this review,
analyzed with intention to treat and with study participants being clinically diagnosed with Rett
Syndrome. Patients were seen in an outpatient setting in all trials and all participants were
clinically diagnosed with Rett Syndrome.
In the first Ellaway study, participants received 100 mg/kg/day of L-carnitine three times
a day and in the follow-up study the same dosage was given twice a day.1,2 In the Guideri study
participants received 50 mg/kg day.3 A total of four participants in all studies experienced very
loose bowel movements so their L-carnitine dosage was lowered to 75 mg/kg/day; however,
constipation is often a problem with Rett Syndrome so patients benefited from the mild
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laxative.1,2 Four other families reported a fishy body or urine odor coming from their
daughters.1,2
Thirty five female participants completed the initial Ellaway trial. The patient’s ages
ranged between 4 and 35 years, with a median of 9 years. At the end of the trial, the mean total
plasma carnitine level was 43μmol/L with a range of 17 to 61μmol/L (normal, 35-65μmol/L).
The mean increase in total plasma carnitine was 23μmol/L with a range of -5 to 68μmol/L. The
mean free plasma carnitine level was 36μmol/L with a range of 15-54μmol/L (normal, 3060μmol/L) and the mean increase in free plasma carnitine was 18μmol/L with a range of -4 to
54μmol/L. In all but three subjects the total and free plasma carnitine increased between preand post-treatment. The outcome of the treatment was measured using the Wilcoxon matchedpair, signed-rank tests. The p-values for the Parent/Caregiver assessment as well as a medical
follow-up are given in Table 2.1
Table 2. Wilcoxon Matched-Pair, Signed-Rank Test Results
P Value of
Parents/Caregivers

P Value of Medical
follow-up

Behavioral/social

0.091

0.006

Orofacial/respiratory

0.087

0.018

Motor assessment/physical signs

0.537

0.284

Hand Apraxia Scale

0.228

0.058

Rett Syndrome Motor Behavior
Assessment

0.015
0.000
Patient Well-Being Index
The change in status reported by parents and/or caregivers and at medical follow-up after
completion of L-carnitine therapy compared to placebo can be seen in Table 3. In the
parent/caregiver completed questionnaires the only significant improvement seen was in the
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subjects’ well-being when treated with L-carnitine relative to their status on the placebo. At
medical follow-up, more subjects improved than worsened in the behavioral/social subscale of
the Rett Syndrome Motor Behavioral questionnaire. Using the Well-Being Index and Hand
Apraxia scale significantly more children improved than worsened or stayed the same on Lcarnitine relative to the placebo.1
Table 3. Change in Status After Completion of L-carnitine Therapy Compared to Status on
Placebo
Improved

Same

Worse

Number

Percent Number
(95%CI)

Percent
(95% CI)

Number

Percent
(95% CI)

Behavioral/social

11

35.5

15

48.4

5

16.1

Orofacial/respiratory

8

25.8

15

48.4

8

25.8

Motor
8
assessment/physical signs

25.8

17

54.8

6

19.4

Hand Apraxia Scale

6

19.4

15

48.4

10

32.3

Patient Well-Being Index

17

54.8

9

29.0

5

16.1

Behavioral/social

19

54.3

12

34.3

4

11.4

Orofacial/respiratory

15

42.9

13

37.1

7

20.0

Motor
19
assessment/physical signs

54.3

8

22.9

8

22.9

Parent /Caregiver
Rett Syndrome Motor
Behavioral Assessment

Medical follow-up
Rett Syndrome Motor
Behavioral Assessment
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Hand Apraxia Scale

28

80.0

1

2.9

6

17.1

Patient Well-Being Index

25

71.4

8

22.9

2

5.7

7

Treatment effects included relative benefit increase (RBI), absolute benefit increase
(ABI), and numbers need to treat (NNT), whose calculation can be seen in Table 4. The RBI was
found to be 1.86% and the ABI was 0.26%. The NNT was found to be 4.1
Table 4. Treatment effects of randomized, placebo-controlled, double-blind crossover trial
CER
0.14%

EER
0.4%

RBI
0.4%- 0.14%
0.14% =
1.86%

ABI
0.4% - 0.14%= 0.26%

NNT
1/ 0.2%= 3.85= 4

Twenty-one female participants completed the follow-up Ellaway study, with an
additional 62 participants in a control group. The participants ranged in age from 7 to 41 years,
with a mean age of 14.4 years. The mean total plasma carnitine concentration at the
commencement of the trials was 35.2μmol/L, with a range of 16.0-54.0μmol/L. At baseline, ten
subjects had low total plasma carnitine. In all cases the total carnitine concentrations increased
between pre- and post treatment with L-carnitine. Table 5 shows the results of paired t-tests and
Wilcoxon matched-pair, signed-ranks tests for the RS:SSI, hand apraxia scale and sleep diary
data. Significant improvement in scores for the RS cases (P<0.05) was seen for sleep efficiency,
sleep latency, and the proportion of total sleep that occurred during the day. Significant
improvement was seen in communication skills, energy level, teeth grinding, and expressive
speech for RS cases based on the RS:SSI (P<0.05). The SF-36 Health Survey and Hand Apraxia
Scale for the cases or controls showed no significant changes.2
Table 5. Paired t-test and Wilcoxon matched-pair, signed-rank test results for outcome
measures for cases and controls.
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Outcome Measures

RS cases

RS cases: low plasma
carnitine

RS controls

RS:SSI (N)

21

10

62

Communication Skills

0.004

0.971

0.726

Energy Level

0.001

0.689

0.500

Teeth Grinding

0.002

0.419

0.565

Expressive Speech

0.011

0.302

0.347

Hand Apraxia Scale (N)

21

10

62

0.782

0.111

0.644

Sleep Diary Data (N)

21

10

60

Total sleep time

0.641

0.754

0.673

Sleep latency

0.026

0.602

0.054

Sleep efficiency

0.005

0.082

0.220

SF-36 Health Survey (N)

18

10

62

Physical functioning

0.269

0.659

0.060

Ten females participated in the Guideri trial, along with 12 control patients. The
participants ranged in age from 2-21 years. Heart rate variability (HRV), corrected QT interval
(QTc), and QTc dispersion (QTcD) were measured by means of a t-test. Three main spectral
components were identified: very low-frequency (VLF) <0.04 Hz, low-frequency (LF) between
0.04-0.15 Hz, and high-frequency component (HF) between 0.15-0.4 Hz. Table 6 demonstrates
the results of the trial group compared to the control group. No significant differences between
the trial and control groups existed at basal condition. After 6-18 months, the control group had
a significant reduction in total power spectrum of HRV (p=0.04) and the LF spectral variable

8
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(p=0.05), but a significantly increased QTcD (p=0.01). In the treatment group, there was a
significant increase in total power, VLF, and LF spectral variables but no significant reduction in
QTcD occurred.3
Table 6. Comparison of spectral variables and QTc interval in control group and trial
group at basal evaluation and after 6-18 months.
R-R
interval

Total
Power
(msec2)

VLF
(msec2)

LF
(msec2
)

HF
(msec2)

LF:HF

QTc (sec)

QTcD
(sec)

Control
Group
(n=12)

p=0.06

p=0.04

p =0.6

p
=0.05

p =0.3

p=0.5

p =0.9

p=0.01

Basal
Evaluatio
n

602 ±
121

1197±
483

332±47

470±
236

171±11
9

4±2.6

0.429±
0.02

0.03±
0.01

After 6-18
mo.

584±78

830±
343

373±
223

286±
195

129±
105

5± 5

0.430 ±
0.02

0.05 ±
0.02

Trial
Group

p =0.6

p =0.01

p =0.01

p
p =0.1
=0.009

p=0.8

p =0.6

p =0.64

Basal
Evaluatio
n

583±61

1004±
430

369±
235

369±
181

2.3±
1.2

0.43± 0.04 0.039±
0.01

191±
116

After 6-18 616± 61 3094±
796±
2.2±
0.425±
0.036±
1003±
963±
mo.
1042
1.8
0.03
0.01
2108
697
564
Treatment effects included the relative risk reduction (RRR), absolute risk reduction
(ARR), and NNT, whose calculation can be seen in Table 7. The RRR was found to be -0.18%
and the ARR was -0.1%. The NNT was found to be -10.3
Table 7. Treatment effects of randomized controlled trial
CER
0.55%

EER
0.45%

RRR
0.45% -0.55%
0.55% = 0.18%

ARR
0.45%-0.55%= - 0.1%

NNT
1/-0.1%= -10

Mason, L-carnitine & Rett Syndrome

10

Discussion
The randomized controlled trials and cohort trial demonstrate that L-carnitine can be used
to improve the quality of life in Rett Syndrome patients by improving symptoms and reducing
the risk of sudden cardiac death.
In the initial Ellaway study, there was improvement in the patient’s well-being according
to parental and/or caregiver assessment but no other improvements were statistically significant.1
The medical follow-up for this study showed significant improvement in the behavior/social and
the orofacial/respiratory subscale of the Motor Behavioral Assessment and Hand Apraxia scale.
Based on qualitative symptomatic data, 70% of parents reported subtle but important
improvements in the quality of life of the subjects while on the L-carnitine phase of the trial.
These improvements included improved eye contact and concentration span, lack of daytime
somnolence, improved vocalization, increased mobility, and the perception that the girls were
much happier. Limitations of this study included subjective assessment tools which were
insensitive to minor improvements in patients and potential unblinding of parents/caregivers and
investigators due to the change in bowel habits of the subjects..1
In the follow-up Ellaway study, Rett Syndrome patients treated with L-carnitine showed
significant improvement over the 6 month period in sleep efficiency, sleep latency, proportion of
total sleep that occurred during the day, energy level, communication skills, expressive language
and teeth grinding.2 In this follow-up study established tools and the RS:SSI were used as
objective outcome measures to assess the effects of L-carnitine on participants. The RS:SSI is a
more reliable and valid assessment tool when compared to those used to assess outcomes in the
initial study.2 One limitation of the study was that the individual improvements of the girls could
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have had significant impact on the patients as well as their families, thus affecting the subjective
outcomes.
The Guideri trial showed that L-carnitine had many effects on ECG parameters. There
was a significant increase in HRV total power and a slight reduction in sympathetic over-activity
(expressed by LF:HF ratio) which can correlate with a reduction of the risk of cardiac
arrhythmias is females with Rett Syndrome.3 A small sample size was studied for this trial
which limits the overall validity of the study.
L-carnitine is currently sold as a nutritional supplement and is used primarily for heartrelated conditions, such as angina.3 It has also been shown to have the potential to prevent
myocardial sympathetic nervous dysfunction in diabetic patients.3
Conclusion
Based on the three trials, L-carnitine does improve the quality of life in patients with Rett
Syndrome. Since there were no baseline criteria for the severity of Rett Syndrome in
participants, the effects of the L-carnitine were varied. Further studies need to be investigated in
which L-carnitine is used for longer than a 6-month period in order to observe any long term
effects of the medication and a baseline severity of Rett Syndrome needs to be established for
participants. Also, researchers need to investigate a way to minimize subjective data in order to
have the data be more statistically significant. Mortality rates and/or annual hospital visits
should be included in future studies of the effect of L-carnitine on cardiac dysautonomia in order
to demonstrate the effect of treatment on patient outcomes.
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